Understanding and Resolving Dyspareunia’s Distress on Women and Clinicians
Sheryl A. Kingsberg, PhD
Professor of Reproductive Biology and Psychiatry
Case Western Reserve University School of Medicine
Of the approximately 64 million women in the United States who are postmenopausal, at least half— estimated at more than 32 million women— have symptoms of vulvovaginal atrophy (VVA) or dyspareunia, or both.1 However, many of these women are unaware that the underlying vulvar and vaginal changes can be the direct result of perimenopause or menopause.1,2 Although these symptoms can be quite bothersome, the majority of women (approximately 93%) fail to seek treatment for them, either owing to embarrassment, lack of knowledge, or negative attitudes/misperceptions regarding hormone therapy.1,3-5 Furthermore, women who do seek treatment are often dissatisfied with the safety, convenience and/or efficacy of currently approved products.1 Consequently, VVA and dyspareunia remain underdiagnosed and undertreated.
Murray A. Freedman, MS, MD, FACOG, IF
Clinical Professor of Obstetrics
Medical College of Georgia
Sheryl A. Kingsberg, PhD
Professor of Reproductive Biology
Case Western Reserve University
School of Medicine
David J. Portman, MD
Director Emeritus, Columbus Center
for Women’s Health Research
Adjunct Instructor of Obstetrics
Ohio State University
Disclosure of Conflicts of Interest:
In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Murray A. Freedman, MS, MD, FACOG, IF Consulting Fees: AMAG Pharmaceuticals; Commercial Interest Speakers Bureau: Valeant Pharmaceuticals; Contracted Research: Procter and Gamble
Sheryl A. Kingsberg, PhD Consulting Fees: AMAG Pharmaceuticals, Emotional Brain, Palatin, Valeant Pharmaceuticals; Commercial Interest Speakers Bureau: AMAG Pharmaceuticals, Palatin, Valeant Pharmaceuticals; Contracted
David J. Portman, MD Consulting Fees: AMAG Pharmaceuticals, Palatin, Valeant Pharmaceuticals; Commercial Interest Speakers Bureau: AMAG Pharmaceuticals, Palatin, Valeant Pharmaceuticals; Contracted Research: Endoceutics
Sean T. Barrett has nothing to disclose.
Carole Drexel, PhD, CHCP has nothing to disclose.
Amanda Hilferty has nothing to disclose.
Ashley Rosenthal has nothing to disclose.
Robert Schneider, MSW has nothing to disclose.
After participating in this educational activity, participants should be better able to:
- Define vulvovaginal atrophy (VVA), and genitourinary syndrome (GSM) and their impact on post-menopausal dyspareunia
- Identify the factors, both clinician-based and patient-based, that may inhibit diagnosis of dyspareunia
- Describe clinician counseling approaches to facilitate a discussion with patients about their symptoms
- Discuss the benefits and risks of innovative therapeutic interventions indicated for the management of menopause-related dyspareunia
ACCREDITATION AND CREDIT DESIGNATION STATEMENTS:
The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The posttest and evaluation of this activity may be taken online by visiting www.omniaeducation.com/dyspareunia. CME credit may also be claimed by faxing the posttest/evaluation to 215.358.0556. A copy of the posttest/evaluation may also be mailed to Omnia Education 500 Office Center Drive, Suite 300 Fort Washington, PA 19034.
Omnia Education has a core focus on women’s health and the ways in which diseases and conditions impact the female patient. That unique focus has transformed the CME learning environment for healthcare professionals nationwide. We impact thousands of clinicians annually, many of whom return each year for clinical updates and connectivity with regional peers.
This activity is supported by an independent educational grant from AMAG Pharmaceuticals Inc.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
- Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) Survey. J Sex Med. 2013;10(7):1790–1799.
- Krychman M, Graham S, Bernick B, et al. The Women’s EMPOWER Survey: Women’s knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. J Sex Med. 2017;14(3):425-433.
- Freedman M. Vaginal pH, estrogen and genital atrophy. Menopause Manage. 2008;17(4):9-13.
- Nappi RE, Kokot-Kierepa M. Women’s voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2010;67(3):233-238.
- Simon JA, Kokot-Kierepa M, Goldstein J, Nappi RE. Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey. Menopause. 2013;20(10):1043-1048.
- Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063-1068.
- American College of Obstetricians and Gynecologists Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin Number 119: Female sexual dysfunction. Obstet Gynecol. 2011;117(4):996-1007.
- Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci. 1990;592:52-86.
- Dennerstein L, Dudley EC, Hopper JL, et al. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000;96(3):351-358.
- Patel D, Gillespie B, Foxman B. Sexual behavior of older women: results of a random-digit-dialing survey of 2,000 women in the United States. Sex Transm Dis. 2003;30(3):216-220.
- Simon JA, Nappi RE, Kingsberg SA, et al. Clarifying Vaginal Atrophy’s Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners. Menopause. 2014;21(2):137-142.
- Thomas HN, Hess R, Thurston RC. Correlates of sexual activity and satisfaction in midlife and older women. Ann Fam Med. 2015;13(4):336-342.
- Kingsberg, S. Millheiser L. Mature women’s attitudes about the impact of sexual concerns on relationship and sexual satisfaction. Abstract P-38. Presented at: North American Menopause Society (NAMS) 2016 Annual Meeting; October 5-8, 2016; Orlando, FL.
- REVEAL. REvealing Vaginal Effects At mid-Life: Surveys of post-menopausal women and health care professionals who treat postmenopausal women. Madison, NJ: Wyeth; 2009.
- Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey. Climacteric. 2012 Feb;15(1):36-44.
- Nappi RE, Kingsberg S, Maamari R, Simon J. The CLOSER (CLarifying Vaginal Atrophy’s Impact On SEx and Relationships) Survey: Implications of vaginal discomfort in postmenopausal women and in male partners. J Sex Med 2013;10:2232–2241.
- Kingsberg SA, Krychman M, Graham S, et al. The Women’s EMPOWER Survey: identifying women’s perceptions on vulvar and vaginal atrophy and its treatment. J Sex Med. 2017;14(3):413-424.
- Bayer CR, Eckstrand KL, Knudson G, et al. Sexual health competencies for undergraduate medical education in North America. J Sex Med. 2017;14(4):535-540.
- Seaborne LA, Prince RJ, Kushner DM. Sexual health education in U.S. physician assistant programs. J Sex Med. 2015;12(5):1158-1164.
- Shindel AW, Parish SJ. Sexuality education in North American medical schools: current status and future directions. J Sex Med. 2013;10(1):3-17.
- Sadovsky R, Alam W, Enecilla M, et al. Sexual problems among a specific population of minority women aged 40-80 years attending a primary care practice. J Sex Med. 2006;3(5):795-803.
- Bachmann GA. The importance of obtaining a sexual history. Am Fam Physician. 2000;62(1):59-60.
- Annon JS. The PLISSIT model: a proposed conceptual scheme for the behavioral treatment of sexual problems. Journal of Sex Education and Therapy. 1976;2(2):1-15.
- The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888-902
Consulting Fees: AMAG Pharmaceuticals, Emotional Brain, Palatin, Valeant Pharmaceuticals; Commercial Interest Speakers Bureau: AMAG Pharmaceuticals, Palatin, Valeant Pharmaceuticals; Contracted Research: Palatin